BNP/CALL/ROCHE GS/265/0.1/20.09.24 Share Price

Warrant

DE000PN8TQR8

Real-time Bid/Ask 16:02:05 01/07/2024 BST
0.39 EUR / 0.4 EUR -5.95% Intraday chart for BNP/CALL/ROCHE GS/265/0.1/20.09.24
Current month+200.00%
1 month+133.33%
Date Price Change
01/07/24 0.39 -7.14%
28/06/24 0.42 -6.67%
27/06/24 0.45 -13.46%
26/06/24 0.52 -5.45%
25/06/24 0.55 +7.84%

Delayed Quote Börse Stuttgart

Last update July 01, 2024 at 08:54 am

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PN8TQR
ISINDE000PN8TQR8
Date issued 26/09/2023
Strike 265 CHF
Maturity 20/09/2024 (81 Days)
Parity 10 : 1
Emission price 0.91
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.28
Lowest since issue 0.068
Spread 0.01
Spread %2.50%

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
249.5 CHF
Average target price
278.1 CHF
Spread / Average Target
+11.44%
Consensus